Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cabometyx
Pharma
Exelixis stock rises as Cabometyx withstands patent challenge
Exelixis' stock price rose on Tuesday after a favorable ruling from a Delaware federal judge effectively blocked Cabometyx generic entry out to 2030.
Angus Liu
Oct 16, 2024 10:37am
Exelixis plots FDA prostate cancer filing despite survival miss
Sep 16, 2024 5:00pm
Exelixis joins Novartis on FDA waiting list in prostate cancer
Jan 25, 2024 8:00am
Exelixis reveals Cabometyx data that led to early trial end
Oct 22, 2023 3:30am
Exelixis ends Cabometyx study after seeing dramatic improvements
Aug 24, 2023 12:54pm
Roche, Exelixis combo triumphs in prostate cancer trial
Aug 21, 2023 9:57am
